EUCTR2014-000952-26-GB
Active, not recruiting
Phase 1
Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk Coronary Plaque Disease - DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
niversity of Edinburgh0 sites202 target enrollmentJuly 4, 2014
ConditionsStable coronary artery disease.MedDRA version: 17.0 Level: PT Classification code 10011078 Term: Coronary artery disease System Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
DrugsBrilique
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Stable coronary artery disease.
- Sponsor
- niversity of Edinburgh
- Enrollment
- 202
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients aged \=40 years with angiographically proven multivessel coronary artery disease defined as at least two major epicardial vessels with any combination of either (a) \>50% luminal stenosis, or (b) previous revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery).
- •2\) Provision of informed consent prior to any study specific procedures
- •3\) Receiving aspirin
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 100
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 150
Exclusion Criteria
- •1\.An acute coronary syndrome within the last 12 months
- •2\.An indication for dual anti\-platelet therapy, such as drug eluting stent
- •3\.Receiving thienopyridine therapy such as clopidogrel or prasugrel
- •4\.Percutaneous coronary intervention or coronary artery bypass graft surgery within the last 3 months
- •5\.Inability or unwilling to give informed consent
- •6\.Women who are pregnant, breastfeeding or of child\-bearing potential (women who have experienced menarche, are pre\-menopausal and have not been sterilised) will not be enrolled into the trial
- •7\.Known hypersensitivity to ticagrelor or one of its excipients
- •8\.Active pathological bleeding or bleeding diathesis
- •9\.Significant thrombocytopenia: platelets \<100 x 109 /L
- •10\. History of intracranial haemorrhage
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)Coronary Artery DiseaseJPRN-UMIN000006698PO Associations for Establishment of Evidence in Interventions4,598
Active, not recruiting
Not Applicable
ACUTE-PRASJPRN-jRCTs031220079Fujimoto Shigeru200
Completed
Phase 4
Dual AntiPlatelet Therapy for Stent Assisted Treatment of Cerebral Aneurysmintracranial aneurysmJPRN-UMIN000022462Kobe City Medical Center General Hospital300
Completed
Not Applicable
Optimum platelet inhibition after coronary artery bypass surgery: a prospective, randomised trial comparing platelet aggregation using low- and medium-dose aspirin and clopidogrelCoronary artery bypass grafting (CABG)SurgeryISRCTN55334531Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)108
Completed
Phase 2
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial InjuryCoronary Artery DiseaseNCT02110303University of Edinburgh220